[{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dipalmitoylphosphatidylglycerol","moa":"Apolipoprotein A-I","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dipalmitoylphosphatidylglycerol","moa":"Apolipoprotein A-I","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abionyx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dipalmitoylphosphatidylglycerol","moa":"Apolipoprotein A-I","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CER-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CER-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Abionyx Pharma \/ Not Applicable"}]